We describe an unusual presentation of toe ulceration in a 39-year-old otherwise healthy man. The left fifth toe was painful for several months with ulceration at the tip. The other toes appeared cyanotic and discolored. Foot pulses were normal. Laboratory testing revealed the platelet count at 1208 thousand/microliter, with hemoglobin 19.2 g/dl and hematocrit 57%. The erythropoietin level was found to be markedly decreased at 1 mU/ml. The patient was given the diagnosis of polycythemia vera with iron deficiency. Phlebotomy was performed and aspirin and cytoreductive therapy with hydroxyurea was prescribed with resolution of the toe ulceration.
Case report
A 39-year-old man was referred to the vascular medicine clinic in December 2004 by his primary care physician for evaluation of peripheral arterial disease. The patient noticed discoloration and discomfort in the left foot which started in November 2003 and became worse in the fall of 2004. The left fifth digit most prominently displayed cyanosis and was chronically painful. A cortisone injection was administered to the toe for suspected neuroma. The toe developed an ulceration and the nail was removed by a podiatrist without improvement in his symptoms. Because of severe pain, an amputation of the left fifth toe was contemplated. He also noticed tightness in his left calf not associated with exertion. Of note, prior to the start of these symptoms, he was physically active and had run in four marathons.
He never smoked, had no family history of premature cardiovascular atherosclerosis, and had no history of hypertension or diabetes mellitus. He occasionally suffered from migraine headaches but never used ergot alkaloids. His only medications were oxycodone and ibuprofen on a prn basis, begun due to the toe pain.
Physical examination revealed a ruddy complexion, regular pulse at 90 bpm and blood pressure of 160/92 mmHg, in both upper extremities. The radial, femoral, popliteal, dorsalis pedis and posterior tibial pulses were normal. Cardiac, pulmonary, abdominal and neurological systems were normal to physical examination. The left fifth toe had ulceration at the tip (Figure 1 ). The rest of the toes appeared cyanotic and discolored. Laboratory investigations revealed: Laboratory studies for collagen vascular diseases and a hypercoagulable state were negative. An electrocardiogram, echocardiogram, venous duplex imaging of lower extremities and magnetic resonance angiography of abdominal and lower extremity vessels were normal. The thrombocytosis and erythrocytosis were suspected as the cause of his clinical signs and symptoms. He was prescribed 325 mg of aspirin each day. 1 A hematology consultation was obtained and the erythropoietin level was found to be markedly decreased at 1 mU/ml. He was given the diagnosis of polycythemia vera with iron deficiency. Phlebotomy was performed and cytoreductive therapy with hydroxyurea was prescribed.
The most recent laboratory investigations in April 2005 revealed: Figure 2 ) and he had resumed running.
Discussion
Multiple factors have been proposed to explain the increased thrombogenesis associated with polycythemia vera, including increased hematocrit, thrombocytosis, impaired fibrinolytic activity, platelet activation, leucocyte activation, endothelial damage, interactions between platelets and endothelium, and an increase in whole blood viscosity. Among them, the increase in viscosity, and hence the impairment of blood flow, is a major factor. The impaired capillary blood flow results in arterial and venous thrombotic manifestations as noted in this case. Deformities developed in the capillaries following the onset of hyperviscosity may be observed directly in the nail bed capillaries. 2 Other potential causes of toe ulceration include thromboangiitis obliterans (Buerger's disease), vasculitis or secondary to embolism. The most important treatment objective is the reduction of the patient's hematocrit to 44% as the frequency of thrombosis in polycythemia vera patients increases at a hematocrit greater than 44%. 3 In women, a lower hematocrit of 42% is recommended, and in pregnancy an even lower value of 36% should be used. 4 Phlebotomy is the mainstay of treatment in polycythemia vera, but is associated with an increased rate of thrombosis when compared with cytoreductive therapy. Cytoreductive therapies have other associated risks, including an increased risk of leukemia, which is greater with alkylating agents than with the antimetabolite hydroxyurea. 5 Patients should be kept well hydrated at all times to reduce the thrombosis risk.
In this patient, the prothrombin time normalized when the hematocrit was reduced. The initially prolonged value was likely due to the relative small plasma volume in the sample compared to the liquid sodium citrate anticoagulant in the standard vacutainor tube. This typically occurs in samples with a hematocrit greater than 55%.
This case illustrates the importance of conducting a baseline laboratory evaluation, including a complete blood count, in evaluating apparent peripheral arterial disease, particularly in patients without risk factors for atherosclerotic disease. 
